Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Novartis' Drug Discovery Head Jay Bradner On What NIBR Is Investing In

Wed, 06/05/2019 - 10:14am

NIBR's Bradner talked to Scrip about how AveXis turbo-charged Novartis' gene therapy development, investing in inflammasome research, and partnering nimbly...

      Related Stories 

How GenomiQa Hopes To Power Improved Outcomes In Cancer

Wed, 06/05/2019 - 9:09am

Colin Albert, CEO of genomiQa, outlines the potential and benefits of whole genome analysis in cancer therapy and research. Expansion...

      Related Stories 

Sanofi Pasteur Head: Global Flu Vaccination Rates 'Dangerously Low'

Wed, 06/05/2019 - 9:07am

The head of Sanofi Pasteur tells Scrip more countries need to emulate the UK’s relatively high flu vaccination level, and...

      Related Stories 

Spotlight on Q1 Pharma M&A Merry-Go-Round

Wed, 06/05/2019 - 7:48am

Q1 2019 saw a jump in merger and acquisition activity. Informa’s Biomedtracker has cast an analytical eye on three of...

      Related Stories 

ASCO Review: Progress Is Where You Find It

Tue, 06/04/2019 - 11:35pm

In another year roundly critiqued as being “quiet” on major clinical advances, the American Society of Clinical Oncology annual meeting...

      Related Stories 

Finance Watch: BIO Report Shows Record VC Funding Across Geographies

Tue, 06/04/2019 - 1:06pm

Private Company Edition: Venture capital for emerging therapeutics companies in the US and in ex-US regions reached all-time highs in...

      Related Stories 

Insurer And Patient Drug Costs Soared For Top-Sellers Over 6-Year Study

Tue, 06/04/2019 - 1:00pm

Median out-of-pocket and insurance costs for 49 high-volume brand-name drugs jumped 79% from 2012 to 2017 in a new analysis...

      Related Stories 

So Far, Still So Good For Seattle Genetics/Astellas’ Bladder Cancer ADC

Mon, 06/03/2019 - 11:01pm

Updated data from the Phase II EV-201 study of Seattle Genetics/Astellas Pharma’s novel ADC are strong enough to warrant accelerated...

      Related Stories 

Lartruvo Could Be A Failure Of The Drug, The Design Or The Disease

Mon, 06/03/2019 - 9:43pm

The presentation of the ANNOUNCE results, the failed confirmatory trial for Lilly’s Lartruvo, at ASCO re-opened questions about the accelerated...

      Related Stories 

Lung Cancer, Conjugates Emerge As Key Asia Company Themes

Mon, 06/03/2019 - 9:21pm

Among Asia Pacific pharma companies presenting new clinical data on their oncology pipelines at ASCO, lung and urothelial cancer and...

      Related Stories 

BIO 2019 Notebook: Merck; Out-Licensing Deals; RMAT

Mon, 06/03/2019 - 5:29pm

News and views from day one of the BIO International Convention: Merck reaffirms commitment to antibiotic space the same day...

      Related Stories 

Sanofi Myeloma Drug Shines But Darzalex Dominates Still

Mon, 06/03/2019 - 6:36am

While data on Sanofi's anti-CD38 antibody isatuximab impressed at ASCO, analysts believe that the position of Johnson & Johnson's Darzalex...

      Related Stories 

Pipeline Watch: Phase III Readouts For QMF149, Korsuva And Valoctocogene Roxaparvovec

Mon, 06/03/2019 - 5:49am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

Pages